The one-dose vaccine developed by Johnson & Johnson is temporarily halted because of potentially serious blood clots seen in six women. An immunologist explains what this means for you.
Articles on Moderna vaccine
Displaying 41 - 60 of 64 articles
New CDC guidance permits domestic travel for fully vaccinated individuals, as long as social distancing is respected. International travel guidelines are different.
Good news for children and young people, bad news for Johnson & Johnson.
Many people never experience the least bit of discomfort from the COVID-19 vaccines, but mild side effects are common. They include swelling in the affected arm, nausea and chills.
An immunologist explains that you get some protection from the first dose of the mRNA vaccines but you need two to build up strong immunity, particularly to newer coronavirus variants.
With four COVID-19 vaccines approved for use in Canada, it’s time to answer FAQs about efficacy, immunity, eradication and variants.
Millions of vaccinated people have been waiting for guidelines on what they can do safely. The CDC says it’s OK to gather with other vaccinated people, but it’s still best to avoid travel.
Researchers are closely watching the coronavirus mutants to make sure vaccines can be adjusted if necessary. But scientists don’t know whether vaccines will be effective in those already vaccinated.
You’ve been vaccinated; can you now safely see your friends and family? New research hints that vaccinated people may be less likely to transmit the coronavirus, but they are not 100% in the clear.
Vaccine hesitancy will not go away fast. In fact, there are parallels in the physical world to how quickly or slowly an object returns to its normal state.
The COVID-19 vaccine rollout has fallen far short of President Trump’s promises. President Biden says he can fix that. Can he?
Two pharmacists involved in COVID-19 vaccine preparation explain the role pharmacists are poised to play in expanding vaccine access.
Rollout of COVID-19 vaccines has begun. But getting the jab doesn’t mean abandoning masks, distancing and handwashing. Here’s why the current preventive measures must continue post-vaccine.
Two in five Americans say they don’t want a COVID-19 vaccine, which is a problem. Finding out what Americans do want from a vaccine might help.
The shipment of goods to suppliers has become technologically sophisticated. Delays in getting out the COVID-19 vaccine to people show that the breakdowns come down to something more basic.
A new strain of the SARS-CoV-2 virus that causes COVID-19 appears to be spreading fast in the UK. This probably isn’t a big problem, but the data isn’t in yet.
Experts from across The Conversation assess the work that’s helped us reach vaccine roll-out, how this could play out, and the risk of vaccine hesitancy.
The development of multiple vaccines against the virus that causes COVID-19 has been hailed as the breakthrough of 2020. But there were many more supporting discoveries that made this possible.
Here’s what we still need to find out before we can know when we’ll be able to return to our pre-coronavirus ways.
We should applaud drug companies for developing COVID-19 vaccines in record time, but let’s not be under any illusion about the profits that are motivating them.
Top contributors
-
Professor of Medicine, University of Virginia
-
Associate Professor and ARC Future Fellow, The University of Western Australia
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Instructor of Human Immunology, Emory University
-
Research associate, Warren Alpert Medical School, Brown University, Brown University
-
Professor of Law, Villanova University
-
Professor, The Children's Hospital at Westmead Clinical School and Sydney Infectious Diseases Institute, University of Sydney
-
Professor, Biology, York University, Canada
-
Pediatric Infectious Diseases Fellow, University of Pittsburgh
-
Professor of Microbiology, School of Medicine, University of Washington
-
Clinician-Scientist Trainee, Faculty of Medicine & Dentistry and Faculty of Science, University of Alberta
-
Adjunct Professor of Epidemiology, University of Texas Health Science Center at Houston
-
Clinical Professor of Pharmacy Practice, University of Connecticut
-
Group Leader: Next-generation Vaccines, Antiviral Gene Therapy Research Unit, University of the Witwatersrand